Patent SG-11201803676P-A (SG)
Title: Site specific her2 antibody drug conjugates
Inventor: MA DANGSHE
IPC: C07K16/32
Filed: 2016-11-22
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 June 2017(08.06.2017) WIPOIPCT (10) International Publication Number WO 2017/093844 A1 (51) International Patent Classification: C07K16/32 (2006.01) A61K 47/68 (2017.01) A61P 35/00 (2006.01) (21) International Application Number: (30) (71) (72) (74) (81) PCT/IB2016/057017 (22) International Filing Date: 22 November 2016 (22.11.2016) (25) Filing Language: (26) Publication Language English Priority Data: 62/260,854 30 November 2015 (30.11.2015) 62/289,744 1 February 2016 (01.02.2016) 62/289,727 1 February 2016 (01.02.2016) 62/409,105 17 October 2016 (17.10.2016) US US us us Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). Inventors: MA, Dangshe; 49 Glenwood Road, Millwood, New York 10546 (US). LOGANZO, JR., Frank; 7 Gregory Street, New City, New York 10956 (US). MAR­ QUETTE, Kimberly Ann; 66 Springfield Street #1, Somerville, Massachusetts 02143 (US). GRAZIANI, Ed­ mund Idris; 497 South Pascack Road, Chestnut Ridge, New York 10977 (US). SAPRA, Puja; 254 Wayne Aven­ ue, River Edge, New Jersey 07661 (US). STROP, Pavel; 461 West 25th Avenue, San Mateo, California 94403 (US). Agent: WALDRON, Roy F.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) with sequence listing part of description (Rule 5.2(a)) < Tf Tf 00 ON n O (54) Title: SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES (57) : The present invention provides site specific HER2antibody drug conjugates and methods for preparing and using the same.